首页> 外国专利> New bi-heteroaryl or phenyl-heteroaryl compounds, are PPAR-gamma receptor modulators useful e.g. for treating dermatological, metabolic or immunological disorders or precancerous lesions

New bi-heteroaryl or phenyl-heteroaryl compounds, are PPAR-gamma receptor modulators useful e.g. for treating dermatological, metabolic or immunological disorders or precancerous lesions

机译:新的双-杂芳基或苯基-杂芳基化合物是有用的例如PPAR-γ受体调节剂。用于治疗皮肤病,代谢或免疫疾病或癌前病变

摘要

3,4'-Disubstituted 1,1'-biphenyl analogs (I), in which at least one phenyl ring is replaced by a heteroaryl ring, are new. Bi-heteroaryl or phenyl-heteroaryl compounds of formula (I) and their optical or geometric isomers and salts are new. [Image] R1 : (2,4-dioxo-thiazolidin-5-yl)-methyl, (2,4-dioxo-thiazolidin-5-ylidene)-methyl or -CH 2-CHR3R4; R2 : 1-12C alkyl, aryl, aralkyl, heteroaryl, heterocyclyl, 9-fluorenylmethyl or -(CH 2) m-(NR5) n-(C(O,N)) p-R6; R3 : 5-(R7)-1,3,4-oxadiazol-2-yl, -CO-R8 or an azole group; R4 : 1-12C alkyl, OR9, SR9 or NHR9; R5, R7 : H, 1-12C alkyl, aryl, aralkyl, heteroaryl or heterocyclyl; R6, R8 : -O-(CH 2) v-R 10, OH, 1-12C alkyl, aryl, aralkyl, heteroaryl, heterocyclyl,-NR'R'' or -N(R')-(CH 2) v-R 10; R9 : 1-12C alkyl, -C 6H 4-R11 or -(CH 2) m-(CO) n-(Q) p-(CH 2) q-R11 or N-protected alpha -aminoacid residue containing a conventional amino-protecting group (e.g. 9-fluorenylmethylcarbamate, tert. butylcarbamate, benzyl or trifluoroacetyl); m, n, p, q : 0-2; Q : O, S or NR5; V : O or S; W : N or C-R5; Y : N or C; Z : O, N or S; v : 1-3; R10 : 1-12C alkyl, aryl, aralkyl, heteroaryl, heterocyclyl, NHCOR12, NHCOOR12, CR12R13 or NR12R13; R' : H, 1-12C alkyl, heteroaryl or heterocyclyl; R'' : H, 1-12C alkyl, aryl, aralkyl (optionally substituted by one or more halo), heteroaryl, heterocyclyl, -(CH 2) v-R10, NHR10 or N(R10) 2; R11 : H, 1-12C alkyl, aryl, aralkyl, heteroaryl, heterocyclyl or -(CO) s(Z) t-R10; R12 : H, 1-12C alkyl, aryl, aralkyl, heteroaryl or heterocyclyl; R13 : H or 1-12C alkyl; X : -(CH 2) z-(NR14) y-(CO) x-(D) w-; D : O, S, NR15 or CH 2; x, y, z : 0 or 1; w : 0-6; R14, R15 : H or 1-12C alkyl; Ar1, Ar2 : phenyl (but not both phenyl), pyridine, pyrimidine, pyrazine, pyridazine, thiophene, furan, 1-(R13)-pyrrole, isoxazole, isothiazole, 1-(R13)-pyrazole, oxazole, thiazole, 1-(R13)-imidazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 4-(R13)-4H-1,2,4-triazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole or 1-(R13)-1H-1,2,4-triazole (all optionally substituted). ACTIVITY : Dermatological; antiseborrheic; immunosuppressive; antiallergic; antiinflammatory; antipsoriatic; antirheumatic; virucide; cytostatic; vulnerary; keratolytic; anorectic; antilipemic; antidiabetic; antiarthritic; antialopecia; antiasthmatic; neuroprotective; antiarteriosclerotic; hypotensive. MECHANISM OF ACTION : Peroxisome proliferator-activated receptor sub-type gamma (PPARgamma ) modulator. In transactivation tests in cultures of HeLa cells transfected with the plasmids ERE-beta Glob-Luc-SV-Neo (reporter) and PPAR (alpha , beta , gamma ) Gal-hPPAR, N-(3-(5-(2,4-dioxo-thiazolidin-5-ylidenyl-methyl)-benzyl)-N-methyl-octanoylamide (Ia) had a K dapparent value of 500 nM for PPARgamma .
机译:3,4'-二取代的1,1'-联苯类似物(I),其中至少一个苯环被杂芳基环取代,是新的。式(I)的双-杂芳基或苯基-杂芳基化合物及其光学或几何异构体和盐是新的。 [图像] R1:(2,4-二氧代噻唑烷-1-基)-甲基,(2,4-二氧代噻唑烷-5-基)-甲基或-CH 2 -CHR3R4; R2:1-12C烷基,芳基,芳烷基,杂芳基,杂环基,9-芴基甲基或-(CH 2)m-(NR5)n-(C(O,N))p-R6; R3:5-(R7)-1,3,4-恶二唑-2-基,-CO-R8或唑基; R4:1-12C烷基,OR9,SR9或NHR9; R5,R7:H,1-12C烷基,芳基,芳烷基,杂芳基或杂环基; R6,R8:-O-(CH 2)v-R 10,OH,1-12C烷基,芳基,芳烷基,杂芳基,杂环基,-NR'R”或-N(R')-(CH 2)v-R 10; R9:1-12C烷基,-C 6H 4-R11或-(CH 2)m-(CO)n-(Q)p-(CH 2)q-R11或含有常规氨基的N-保护的α-氨基酸残基-保护基(例如9-芴基甲基氨基甲酸酯,叔丁基氨基甲酸酯,苄基或三氟乙酰基); m,n,p,q:0-2; Q:O,S或NR 5; V:O或S; W:N或C-R5; Y:N或C; Z:O,N或S; v:1-3; R10:1-12C烷基,芳基,芳烷基,杂芳基,杂环基,NHCOR12,NHCOOR12,CR12R13或NR12R13; R':H,1-12C烷基,杂芳基或杂环基; R”:H,1-12C烷基,芳基,芳烷基(任选地被一个或多个卤素取代),杂芳基,杂环基,-(CH 2)v-R10,NHR10或N(R10)2; R11:H,1-12C烷基,芳基,芳烷基,杂芳基,杂环基或-(CO)s(Z)t-R10; R12:H,1-12C烷基,芳基,芳烷基,杂芳基或杂环基; R13:H或1-12C烷基; X :-( CH 2)z-(NR14)y-(CO)x-(D)w-; D:O,S,NR 15或CH 2; x,y,z:0或1; w:0-6; R14,R15:H或1-12C烷基; Ar1,Ar2:苯基(但不是全部都是苯基),吡啶,嘧啶,吡嗪,哒嗪,噻吩,呋喃,1-(R13)-吡咯,异恶唑,异噻唑,1-(R13)-吡唑,恶唑,噻唑,1- (R13)-咪唑,1,3,4-恶二唑,1,3,4-噻二唑,4-(R13)-4H-1,2,4-三唑,1,2,4-恶二唑,1,2, 4-噻二唑或1-(R13)-1H-1,2,4-三唑(全部任选取代)。活动:皮肤科;抗脂溢性;免疫抑制抗过敏消炎(药;牛皮癣抗风湿性杀病毒剂细胞生长抑制伤药;溶角蛋白厌食的抗血脂抗糖尿病抗关节炎抗脱发抗哮喘神经保护抗动脉硬化;低血压。作用机理:过氧化物酶体增殖物激活的受体亚型γ(PPARgamma)调节剂。在用质粒ERE-beta Glob-Luc-SV-Neo(报道基因)和PPAR(alpha,beta,γ)Gal-hPPAR转染的HeLa细胞培养物中的反式激活测试中,N-(3-(5-(2,4 -二氧代-噻唑啉基-5-亚甲基(甲基)-苄基)-N-甲基-辛酰基酰胺(Ia)的PPARγ的K dapparent值为500 nM。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号